We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Anastrozole and Letrozole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00762294
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : December 15, 2011
Information provided by (Responsible Party):

September 26, 2008
September 30, 2008
December 15, 2011
May 2007
December 2011   (Final data collection date for primary outcome measure)
bone density [ Time Frame: baseline, 6 months, 12 months ]
Same as current
Complete list of historical versions of study NCT00762294 on ClinicalTrials.gov Archive Site
bone markers [ Time Frame: baseline, 1 month, 3 month, 6 month, 12 month ]
Same as current
Not Provided
Not Provided
Anastrozole and Letrozole
Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study

Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer. However, because these medications produce a marked reduction in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures in postmenopausal women treated with these agents. Indeed, substantial bone loss has been reported in several large clinical trials of AIs. Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive. Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach. A better approach might be to select women at highest risk of bone loss and only treat them with antiresorptive agents.

The proposed pilot study will evaluate women who receive anastrozole or letrozole therapy, are receiving adequate amounts of calcium and vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover markers correlate with bone loss at one year. If data from this pilot protocol support our hypothesis, then we would propose a larger trial to confirm it. The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.

Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Women receiving treatment for breast cancer, who will be starting Arimidex or Femara
Breast Cancer
Not Provided
Women treated for breast cancer who will be starting Arimidex or Femara
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postmenopausal women with diagnosis of breast cancer - have not started Arimidex or Femara yet, but will be starting .

Exclusion Criteria:

  • History of metastasis
  • History of chronic kidney
  • Liver GI disease
  • Disorders affecting calcium metabolism
Sexes Eligible for Study: Female
40 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
GCRC # 644
Not Provided
Not Provided
Pamela Taxel, University of Connecticut Health Center
UConn Health
Connecticut Breast Health Initiative
Principal Investigator: Pamela Taxel, MD UConn Health
UConn Health
December 2011